Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
CSTL Stock Chart & Stats
$34.97
-$0.86(-2.67%)
At close: 4:00 PM EST
$34.97
-$0.86(-2.67%)
Day’s Range― - ―
52-Week Range$14.59 - $35.49
Previous CloseN/A
Volume108.23K
Average Volume (3M)381.89K
Market Cap
$1.01B
Enterprise Value$411.59M
Total Cash (Recent Filing)$287.54M
Total Debt (Recent Filing)$37.14M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Mar 04, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding29,188,660
10 Day Avg. Volume609,817
30 Day Avg. Volume381,887
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)1.62
Price to Sales (P/S)2.23
P/FCF Ratio20.26
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue1.20
Enterprise Value/Gross Profit1.50
Enterprise Value/Ebitda15.96
Forecast
1Y Price Target
$34.39Price Target Upside-1.66% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.81
Revenue Forecast (FY)$317.42M
Bulls Say, Bears Say
Bulls Say
EarningsShares of CSTL are up +20% after CSTL delivered a solid 17% topline Q3 beat and raised the FY outlook $4M above the magnitude of the Q3 beat.
Market ValuationShares of CSTL trade at just 1.7x the 2027 revenue estimate of $372M, below its SMID clinical peers, suggesting potential for further upside.
Product LaunchCSTL announced the new commercial launch of AdvanceAD-Tx, a test designed to guide treatments for patients with atopic dermatitis, with a sizable target market of $33 billion.
Bears Say
Castle Biosciences News
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $14.59 and its highest was $35.49 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $1.01B.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Mar 04, 2026 which is in 110 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Nov 03, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.521 by $0.501.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Overvalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.34.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 29,188,660 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.521. Following the earnings report the stock price went up 21.701%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.39 (-1.66% Downside)
$34.39 (-1.66% Downside)
Blogger Sentiment
Bullish
CSTL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 68.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $390.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.7%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.52%
12-Months-Change
Fundamentals
Return on Equity
-2.69%
Trailing 12-Months
Asset Growth
9.37%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
CSTL Company Deck
CSTL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Castle Biosciences demonstrated strong revenue growth, launched a new dermatological test, and achieved record test report volumes. However, challenges include a decline in gross margin, reporting a net loss, and uncertainties in SCC reimbursement. Despite these challenges, the company's positive momentum and strategic initiatives suggest a well-balanced performance.View all CSTL earnings summariesCSTL Stock 12 Month Forecast
Average Price Target
$34.39
▼(-1.66% Downside)
Technical Analysis
Ownership Overview
2.61% Insiders
28.97% Mutual Funds
0.10% Other Institutional Investors
54.54% Public Companies and
Individual Investors